Comparative of the effect about CAVI between Luseogliflozin and Amaryl in type2 diabetes
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Glimepiride (Primary) ; Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 05 Apr 2019 According to UMIN, the date for data entry closure is 31 Jan 2019, and the date for conclusion of data analysis is 31 March 2019.
- 05 Apr 2019 Status changed from not yet recruiting to completed.
- 27 Jan 2017 New trial record